[Federal Register Volume 79, Number 241 (Tuesday, December 16, 2014)]
[Notices]
[Pages 74783-74784]
[FR Doc No: 2014-29365]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-73810; File No. SR-NYSEArca-2014-107]

Self-Regulatory Organizations; NYSE Arca, Inc.; Notice of
Designation of a Longer Period for Commission Action on Proposed Rule
Change, as Modified by Amendment No. 1 Thereto, To Reflect Changes to
the Means of Achieving the Investment Objective Applicable to the
Guggenheim Enhanced Short Duration ETF

December 10, 2014.
    On October 21, 2014, NYSE Arca, Inc. (``Exchange'') filed with the
Securities and Exchange Commission (``Commission''), pursuant to
Section 19(b)(1) of the Securities Exchange Act of 1934 (``Act'') \1\
and Rule 19b-4 thereunder,\2\ a proposed rule change to reflect changes
to the description of the measures the Adviser of the Guggenheim
Enhanced Short Duration ETF will utilize to implement the fund's
investment objectives. On October 29, 2014, the Exchange filed
Amendment No. 1 to the proposed rule change. The proposed rule change
was published for comment in the Federal Register on November 7,
2014.\3\ The Commission received one comment on the proposal.\4\
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ See Securities Exchange Act Release No. 73512 (Nov. 3,
2014), 79 FR 66442.
    \4\ All comments on the proposed rule change, including
Amendment No. 1, are available on the Commission's Web site at:
http://www.sec.gov/comments/sr-nysearca-2014-107/nysearca2014107.shtml.
---------------------------------------------------------------------------

    Section 19(b)(2) of the Act \5\ provides that within 45 days of the
publication of notice of the filing of a proposed rule change, or
within such longer period up

to 90 days as the Commission may designate if it finds such longer
period to be appropriate and publishes its reasons for so finding, or
as to which the self-regulatory organization consents, the Commission
shall either approve the proposed rule change, disapprove the proposed
rule change, or institute proceedings to determine whether the proposed
rule change should be disapproved. The 45th day after publication of
the notice for this proposed rule change is December 22, 2014. The
Commission is extending this 45-day time period.
---------------------------------------------------------------------------

    \5\ 15 U.S.C. 78s(b)(2).
---------------------------------------------------------------------------

    The Commission finds it appropriate to designate a longer period
within which to take action on the proposed rule change so that it has
sufficient time to consider this proposed rule change. Accordingly, the
Commission, pursuant to Section 19(b)(2) of the Act,\6\ designates
February 5, 2015, as the date by which the Commission shall either
approve or disapprove, or institute proceedings to determine whether to
disapprove, the proposed rule change (File No. SR-NYSEArca-2014-107)
---------------------------------------------------------------------------

    \6\ Id.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\7\
---------------------------------------------------------------------------

    \7\ 17 CFR 200.30-3(a)(31).
---------------------------------------------------------------------------

Kevin M. O'Neill,
Deputy Secretary.
[FR Doc. 2014-29365 Filed 12-15-14; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 79, Number 231 (Tuesday, December 2, 2014)]
[Notices]
[Page 71464]
[FR Doc No: 2014-28308]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

Submission for OMB Review; Comment Request

Upon Written Request, Copies Available From: U.S. Securities and
Exchange Commission, Office of FOIA Services, Washington, DC 20549-
2736.

Extension:
    Rule 15c1-5, SEC File No. 270-422, OMB Control No. 3235-0471.

    Notice is hereby given that pursuant to the Paperwork Reduction Act
of 1995 (``PRA'') (44 U.S.C. 3501 et seq.), the Securities and Exchange
Commission (``Commission'') has submitted to the Office of Management
and Budget (``OMB'') a request for approval of extension of the
previously approved collection of information provided for in Rule
15c1-5 (17 CFR 240.15c1-5) under the Securities Exchange Act of 1934
(15 U.S.C. 78a et seq.).
    Rule 15c1-5 states that any broker-dealer controlled by,
controlling, or under common control with the issuer of a security that
the broker-dealer is trying to sell to or buy from a customer must give
the customer written notification disclosing the control relationship
at or before completion of the transaction. The Commission estimates
that 223 respondents collect information annually under Rule 15c1-5 and
that each respondent would spend approximately 10 hours per year
collecting this information (2,230 hours in aggregate). There is no
retention period requirement under Rule 15c1-5. This Rule does not
involve the collection of confidential information.
    An agency may not conduct or sponsor, and a person is not required
to respond to, a collection of information under the PRA unless it
displays a currently valid OMB control number.
    The public may view background documentation for this information
collection at the following Web site: www.reginfo.gov. Comments should
be directed to: (i) Desk Officer for the Securities and Exchange
Commission, Office of Information and Regulatory Affairs, Office of
Management and Budget, Room 10102, New Executive Office Building,
Washington, DC 20503 or by sending an email to:
<EMAIL_ADDRESS>and (ii) Pamela Dyson, Acting Director/
Chief Information Officer, Securities and Exchange Commission, c/o Remi
Pavlik-Simon, 100 F Street NE., Washington, DC 20549 or by sending an
email to<EMAIL_ADDRESS>Comments must be submitted within 30 days
of this notice.

    Dated: November 25, 2014.
Kevin M. O'Neill,
Deputy Secretary.
[FR Doc. 2014-28308 Filed 12-1-14; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 80, Number 190 (Thursday, October 1, 2015)]
[Notices]
[Pages 59156-59160]
[FR Doc No: 2015-24835]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Docket No. FDA-2015-N-0001]

Request for Nominations for Individuals and Consumer
Organizations for Advisory Committees

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is requesting that any
consumer organizations interested in participating in the selection of
voting and/or nonvoting consumer representatives to serve on its
advisory committees or panels notify FDA in writing. FDA is also
requesting nominations for voting and/or nonvoting consumer
representatives to serve on advisory committees and/or panels for which
vacancies currently exist or are expected to occur in the near future.
Nominees recommended to serve as a voting or nonvoting consumer
representative may be self-nominated or may be nominated by a consumer
organization. Nominations will be accepted for current vacancies and
for those that will or may occur through December 31, 2015.

DATES: Any consumer organization interested in participating in the
selection of an appropriate voting or nonvoting member to represent
consumer interests on an FDA advisory

committee or panel may send a letter or email stating that interest to
FDA (see ADDRESSES) by November 2, 2015, for vacancies listed in this
notice. Concurrently, nomination materials for prospective candidates
should be sent to FDA (see ADDRESSES) by November 2, 2015.

ADDRESSES: All statements of interest from consumer organizations
interested in participating in the selection process and consumer
representative nominations should submit information electronically to
<EMAIL_ADDRESS>or by mail to Advisory Committee
Oversight and Management Staff, 10903 New Hampshire Ave., Bldg. 32, Rm.
5103, Silver Spring, MD 20993-0002, or FAX:<PHONE_NUMBER>.
    Consumer representative nominations should be submitted
electronically by logging into the FDA Advisory Committee Membership
Nomination Portal, https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm, or by mail to Advisory Committee Oversight and
Management Staff, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103, Silver
Spring, MD 20993-0002, or FAX:<PHONE_NUMBER>.
    Additional information about becoming a member on an FDA advisory
committee can also be obtained by visiting FDA's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm.

FOR FURTHER INFORMATION CONTACT: Kimberly Hamilton, Advisory Committee
Oversight and Management Staff, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 5117, Silver Spring, MD 20993-0002, 301
796-8224, email<EMAIL_ADDRESS>    For questions relating to specific advisory committees or panels,
contact the persons listed in Table 1:

                  Table 1--Advisory Committee Contacts
------------------------------------------------------------------------
             Contact person                      Committee/Panel
------------------------------------------------------------------------
Shanika Craig, Center for Devices and    Anesthesiology and Respiratory
 Radiological Health, Food and Drug       Therapy Devices Panel.
 Administration, 10903 New Hampshire
 Ave., Bldg. 66, Rm. 1613, Silver
 Spring, MD 20993-0002, Phone: 301-796-
 6639, Email<EMAIL_ADDRESS>Dimitrus Culbreath, Center for Devices   Circulatory System Devices
 and Radiological Health, Food and Drug   Panel; Molecular and Clinical
 Administration, 10903 New Hampshire      Genetics Panel.
 Ave., Bldg. 31, Rm. 3530, Silver
 Spring, MD 20993, Phone:<PHONE_NUMBER>,
 Email<EMAIL_ADDRESS>Sara Anderson, Center for Devices and    Dental Products Device Panel;
 Radiological Health, Food and Drug       Hematology and Pathology
 Administration, 10903 New Hampshire      Devices Panel.
 Ave., Bldg. 66, Rm. 1544, Silver
 Spring, MD 20993-0002, Phone: 301-796-
 1643, Email<EMAIL_ADDRESS>Yvette Waples, Center for Drug           Dermatologic and Ophthalmic
 Evaluation and Research, Food and Drug   Drugs Advisory Committee;
 Administration, 10903 New Hampshire      Pharmaceutical Science &
 Ave., Bldg. 31, Rm. 2510, Silver         Clinical Pharmacology Advisory
 Spring, MD 20993-0002, Phone: 301-796-   Committee.
 9034, Email<EMAIL_ADDRESS>Patricio Garcia, Center for Devices and  General and Plastic Surgery
 Radiological Health, Food and Drug       Devices Panel; Neurological
 Administration, 10903 New Hampshire      Devices Panel.
 Ave., Bldg. 66, Rm. 1535, Silver
 Spring, MD 20993-0002, Phone: 301-796-
 6875, Email:
<EMAIL_ADDRESS>Natasha Facey, Center for Devices and    General Hospital and Personal
 Radiological Health, Food and Drug       Use Devices Panel; Ophthalmic
 Administration, 10903 New Hampshire      Devices Panel.
 Ave., Bldg. 66, Rm. 1552, Silver
 Spring, MD 20993-0002, Phone: 301-796-
 5290, FAX:<PHONE_NUMBER>, Email:
<EMAIL_ADDRESS>Rakesh Raghuwanshi, Office of the        Science Advisory Board to the
 Commissioner, Food and Drug              Food and Drug Administration.
 Administration, 10903 New Hampshire
 Ave., Bldg. 1, Rm. 4308, Silver
 Spring, MD 20993-0002, Phone: 301-796-
 4769, Email:
<EMAIL_ADDRESS>Donna Mendrick, National Center for      Science Advisory Board to
 Toxicological Research, Food and Drug    National Center for
 Administration, 10903 New Hampshire      Toxicological Research (NCTR).
 Ave., Bldg. 32, Rm. 2208, Silver
 Spring, MD 20993-0002, Phone: 301-796-
 8892, FAX:<PHONE_NUMBER>, Email:
<EMAIL_ADDRESS>Sujata Vijh, Center for Biologics        Vaccines and Related Biological
 Evaluation and Research, Food and Drug   Products Advisory Committee.
 Administration, 10903 New Hampshire
 Ave., Bldg. 71, Rm. 6128, Silver
 Spring, MD 20993-0002, Phone: 240-402-
 7107, Email<EMAIL_ADDRESS>------------------------------------------------------------------------

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for voting
and/or nonvoting consumer representatives for the vacancies listed in
table 2:

      Table 2--Committee Descriptions, Type of Consumer Representative Vacancy, and Approximate Date Needed
----------------------------------------------------------------------------------------------------------------
   Committee/Panel/Areas of expertise
                 needed                            Type of vacancy                  Approximate date needed
----------------------------------------------------------------------------------------------------------------
Anesthesiology and Respiratory Therapy   One Non-Voting.....................  Immediately.
 Devices Panel of the Medical Devices
 Advisory Committee--Anesthesiologists,
 pulmonary medicine specialists, or
 other experts who have specialized
 interests in ventilator support,
 pharmacology, physiology, or the
 effects and complications of
 anesthesia.
Circulatory System Devices Panel of the  One Non-Voting.....................  Immediately.
 Medical Devices Advisory Committee--
 Knowledgeable in the safety and
 effectiveness of marked and
 investigational devices for use in the
 circulatory and vascular systems.
Dental Products Devices Panel of the     One Non-Voting.....................  Immediately.
 Medical Devices Advisory Committee--
 Dentists, engineers and scientists who
 have expertise in the areas of dental
 implants, dental materials,
 periodontology, tissue engineering,
 and dental anatomy.
Dermatologic and Ophthalmic Drugs        One Voting.........................  Immediately.
 Advisory Committee--Knowledgeable in
 the fields of dermatology,
 ophthalmology, internal medicine,
 pathology, immunology, epidemiology or
 statistics, and other related
 professions.
General and Plastic Surgery Devices      One Non-Voting.....................  Immediately.
 Panel of the Medical Devices Advisory
 Committee--Knowledgeable in the fields
 of general, plastic, reconstructive,
 pediatric, thoracic, abdominal,
 pelvic, and endoscopic surgery;
 biomaterials, lasers, wound healing,
 and quality of life issues.
General Hospital and Personal Use        One Non-Voting.....................  Immediately.
 Devices Panel of the Medical Devices
 Advisory Committee--Internists,
 pediatricians, neonatologists,
 endocrinologists, gerontologists,
 nurses, biomedical engineers or
 microbiologists, infection control
 practitioners or experts.
Hematology and Pathology Devices Panel   One Non-Voting.....................  Immediately.
 of the Medical Devices Advisory
 Committee --Knowledgeable in the
 fields of hematology, hematopathology,
 coagulation and homeostasis,
 hematological oncology, and
 gynecological oncology.
Molecular and Clinical Genetics Panel    One Non-Voting.....................  Immediately.
 of the Medical Devices Advisory
 Committee--Experts in human genetics
 and in the clinical management of
 patients with genetic disorders, e.g.,
 pediatricians, obstetricians,
 neonatologists. The Agency is also
 interested in considering candidates
 with training in inborn errors of
 metabolism, biochemical and/or
 molecular genetics, population
 genetics, epidemiology, and related
 statistical training. Additionally,
 individuals with experience in genetic
 counseling, medical ethics, as well as
 ancillary fields of study will be
 considered.
Neurological Devices Panel of the        One Non-Voting.....................  Immediately.
 Medical Devices Advisory Committee--
 Neurosurgeons (cerebrovascular and
 pediatric), neurologists (stroke,
 pediatric, pain management, and
 movement disorders), interventional
 neuroradiologists, psychiatrists, and
 biostatisticians.
Obstetrics and Gynecology Devices Panel  One Non-Voting.....................  Immediately.
 of the Medical Devices Advisory
 Committee--Knowledgeable in the fields
 of perinatology, embryology,
 reproductive endocrinology, pediatric
 gynecology, gynecological oncology,
 operative hysteroscopy, pelviscopy,
 electrosurgery, laser surgery,
 assisted reproductive technologies,
 contraception, postoperative
 adhesions, and cervical cancer and
 colposcopy; obstetrics/gynecology
 devices; gynecology in the older
 patient; midwifery; and labor and
 delivery nursing.
Ophthalmic Devices Panel of the Medical  One Non-Voting.....................  Immediately.
 Devices Advisory Committee--
 Ophthalmologists with expertise in
 corneal-external disease, vitreo-
 retinal surgery, glaucoma, ocular
 immunology, ocular pathology;
 optometrists; vision scientists; and
 ophthalmic professionals with
 expertise in clinical trial design,
 quality of life assessment,
 electrophysiology, low vision
 rehabilitation, and biostatistics.
Pharmaceutical Science and Clinical      One Voting.........................  Immediately.
 Pharmacology Advisory Committee--
 Knowledgeable in the fields of
 pharmaceutical manufacturing, clinical
 pharmacology, pharmacokinetics,
 bioavailability and bioequivalence
 research, the design and evaluation of
 clinical trials, laboratory analytical
 techniques, pharmaceutical chemistry,
 physiochemistry, biochemistry,
 biostatistics, and related biomedical
 and pharmacological specialties.
Science Board Advisory Committee for     One Voting.........................  Immediately.
 the Food and Drug Administration--
 Knowledgeable in the fields of food
 science, safety, and nutrition;
 chemistry; pharmacology; translational
 and clinical medicine and research;
 toxicology; biostatistics; medical
 devices; imaging; robotics; cell and
 tissue based products; regenerative
 medicine; public health and
 epidemiology; international health and
 regulation; product safety; product
 manufacturing sciences and quality;
 and other scientific areas relevant to
 FDA regulated products such as systems
 biology, informatics, nanotechnology,
 and combination products.
Science Advisory Board to the NCTR--     One Voting.........................  Immediately.
 Knowledgeable in the fields related to
 toxicological research.
Vaccines and Related Biological          One Voting.........................  Immediately.
 Products--Knowledgeable in the fields
 of immunology, molecular biology,
 rDNA, virology, bacteriology,
 epidemiology or biostatistics,
 allergy, preventive medicine,
 infectious diseases, pediatrics,
 microbiology, and biochemistry.
----------------------------------------------------------------------------------------------------------------

I. Functions and General Description of the Committee Duties

A. Certain Panels of the Medical Devices Advisory Committee

    The committee reviews and evaluates data on the safety and
effectiveness of marketed and investigational devices and makes
recommendations for their regulation. The panels engage in a number of
activities to fulfill the functions the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) envisions for device advisory panels. With
the exception of the Medical Devices Dispute Resolution Panel, each
panel, according to its specialty area, advises the Commissioner of
Food and Drugs (the Commissioner) regarding recommended classification
or reclassification of devices into one of three regulatory categories,
advises on any possible risks to health associated with the use of
devices, advises on formulation of product development

protocols, reviews premarket approval applications for medical devices,
reviews guidelines and guidance documents, recommends exemption of
certain devices from the application of portions of the FD&C Act,
advises on the necessity to ban a device, and responds to requests from
the Agency to review and make recommendations on specific issues or
problems concerning the safety and effectiveness of devices. With the
exception of the Medical Devices Dispute Resolution Panel, each panel,
according to its specialty area, may also make appropriate
recommendations to the Commissioner on issues relating to the design of
clinical studies regarding the safety and effectiveness of marketed and
investigational devices. The Dental Products Panel also functions at
times as a dental drug panel. The functions of the dental drug panel
are to evaluate and recommend whether various prescription drug
products should be changed to over-the-counter status and to evaluate
data and make recommendations concerning the approval of new dental
drug products for human use.

B. Dermatologic and Ophthalmic Drugs Advisory Committee

    Reviews and evaluates available data concerning the safety and
effectiveness of marketed and investigational human drug products for
use in the treatment of dermatologic and ophthalmic disorders.

C. Pharmaceutical Science and Clinical Pharmacology Advisory Committee

    Provide advice on scientific and technical issues concerning the
safety and effectiveness of human generic drug products for use in the
treatment of a broad spectrum of human diseases, and as required, any
other product for which the FDA has regulatory responsibility. The
committee may also review Agency sponsored intramural and extramural
biomedical research programs in support of FDA's generic drug
regulatory responsibilities.

D. Science Board

    Provides advice primarily to the Commissioner of Food and Drugs and
other appropriate officials on specific complex and technical issues as
well as emerging issues in the scientific community, industry, and
academia. Additionally, the Board will provide advice to the Agency on
keeping pace with technical and scientific evolutions in the fields of
regulatory science, on formulating an appropriate research agenda, and
on upgrading its scientific and research facilities to keep pace with
these changes. It will also provide the means for critical review of
Agency sponsored intramural and extramural scientific research
programs.

E. Science Advisory Board to the National Center for Toxicological
Research

    Reviews and advises the Agency on the establishment,
implementation, and evaluation of the research programs and regulatory
responsibilities as it relates to NCTR. The Board will also provide an
extra-Agency review in ensuring that the research programs at NCTR are
scientifically sound and pertinent.

F. Vaccines and Related Biological Products Advisory Committee

    Reviews and evaluates data concerning the safety, effectiveness,
and appropriate use of vaccines and related biological products which
are intended for use in the prevention, treatment, or diagnosis of
human diseases, as well as considers the quality and relevance of FDA's
research program which provides scientific support for the regulation
of these products.

II. Criteria for Members

    Persons nominated for membership as consumer representatives on
committees or panels should meet the following criteria: (1)
Demonstrate ties to consumer and community-based organizations, (2) be
able to analyze technical data, (3) understand research design, (4)
discuss benefits and risks, and (5) evaluate the safety and efficacy of
products under review. The consumer representative should be able to
represent the consumer perspective on issues and actions before the
advisory committee; serve as a liaison between the committee and
interested consumers, associations, coalitions, and consumer
organizations; and facilitate dialogue with the advisory committees on
scientific issues that affect consumers.

III. Selection Procedures

    Selection of members representing consumer interests is conducted
through procedures that include the use of organizations representing
the public interest and public advocacy groups. These organizations
recommend nominees for the Agency's selection. Representatives from the
consumer health branches of Federal, State, and local governments also
may participate in the selection process. Any consumer organization
interested in participating in the selection of an appropriate voting
or nonvoting member to represent consumer interests should send a
letter stating that interest to FDA (see ADDRESSES) within 30 days of
publication of this document.
    Within the subsequent 30 days, FDA will compile a list of consumer
organizations that will participate in the selection process and will
forward to each such organization a ballot listing at least two
qualified nominees selected by the Agency based on the nominations
received, together with each nominee's current curriculum vitae or
resume. Ballots are to be filled out and returned to FDA within 30
days. The nominee receiving the highest number of votes ordinarily will
be selected to serve as the member representing consumer interests for
that particular advisory committee or panel.

IV. Nomination Procedures

    Any interested person or organization may nominate one or more
qualified persons to represent consumer interests on the Agency's
advisory committees or panels. Self-nominations are also accepted.
Nominations should include a cover letter and current curriculum vitae
or resume for each nominee, including a current business and/or home
address, telephone number, and email address if available, and a list
of consumer or community-based organizations for which the candidate
can demonstrate active participation. FDA seeks to include the views of
women and men, members of all racial and ethnic groups, and individuals
with and without disabilities on its advisory committees and,
therefore, encourages nominations of appropriately qualified candidates
from these groups.
    Nominations should also specify the advisory committee(s) or
panel(s) for which the nominee is recommended. In addition, nominations
should include confirmation that the nominee is aware of the
nomination, unless self-nominated. FDA will ask potential candidates to
provide detailed information concerning such matters as financial
holdings, employment, and research grants and/or contracts to permit
evaluation of possible sources of conflicts of interest. Members will
be invited to serve for terms up to 4 years.
    FDA will review all nominations received within the specified
timeframes and prepare a ballot containing the names of qualified
nominees. Names not selected will remain on a list of eligible nominees
and be reviewed periodically by FDA to determine continued interest.
Upon selecting qualified nominees for the ballot, FDA will provide
those consumer organizations that are participating in the selection
process with the opportunity to vote on the listed nominees. Only
organizations

vote in the selection process. Persons who nominate themselves to serve
as voting or nonvoting consumer representatives will not participate in
the selection process.

    Dated: September 25, 2015.
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2015-24835 Filed 9-30-15; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 82, Number 39 (Wednesday, March 1, 2017)]
[Notices]
[Page 12219]
[FR Doc No: 2017-03926]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ID-8091-000]

Fitzgerald, Brian; Notice of Filing

    Take notice that on February 21, 2017, Brian Fitzgerald filed a
supplement to application for authorization to hold interlocking
positions, pursuant to section 305(b) of the Federal Power Act, 16
U.S.C. 825d(b), Part 45 of the Federal Energy Regulatory Commission's
(Commission) Rules of Practice and Procedure, 18 CFR part 45, and
Commission Order No. 664, 112 FERC 61,298.
    Any person desiring to intervene or to protest this filing must
file in accordance with Rules 211 and 214 of the Commission's Rules of
Practice and Procedure (18 CFR 385.211, 385.214). Protests will be
considered by the Commission in determining the appropriate action to
be taken, but will not serve to make protestants parties to the
proceeding. Any person wishing to become a party must file a notice of
intervention or motion to intervene, as appropriate. Such notices,
motions, or protests must be filed on or before the comment date. On or
before the comment date, it is not necessary to serve motions to
intervene or protests on persons other than the Applicant.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper using the ``eFiling'' link at http://www.ferc.gov. Persons unable to file electronically should submit an
original and 5 copies of the protest or intervention to the Federal
Energy Regulatory Commission, 888 First Street NE., Washington, DC
20426.
    This filing is accessible on-line at http://www.ferc.gov, using the
``eLibrary'' link and is available for electronic review in the
Commission's Public Reference Room in Washington, DC. There is an
``eSubscription'' link on the Web site that enables subscribers to
receive email notification when a document is added to a subscribed
docket(s). For assistance with any FERC Online service, please email
<EMAIL_ADDRESS>or call<PHONE_NUMBER> (toll free). For
TTY, call<PHONE_NUMBER>.
    Comment Date: 5:00 p.m. Eastern Time on March 3, 2017.

    Dated: February 23, 2017.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2017-03926 Filed 2-28-17; 8:45 am]
BILLING CODE 6717-01-P